Sugi Predict

Sugi Predict / Compounds / SCHEMBL2179728

SCHEMBL2179728

SCHEMBL2179728

COC(=O)c1c(N)sc2c1CCCC2

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 15/20 0.70
▸ MAPT P10636 11/20 0.70
▸ HSD17B10 Q99714 9/20 0.70
▸ KDM4E B2RXH2 9/20 0.70
▸ HPGD P15428 8/20 0.70
▸ ALOX15 P16050 6/20 0.70
▸ GAA P10253 3/20 0.70
▸ MAPK1 P28482 2/20 0.70
▸ MEN1 O00255 6/20 0.65
▸ KMT2A Q03164 6/20 0.65
▸ TSHR P16473 2/20 0.65
▸ CASP1 P29466 1/20 0.65
▸ CASP7 P55210 1/20 0.65
▸ USP2 O75604 2/20 0.65
▸ SMN1; SMN2 Q16637 2/20 0.63
▸ THRB P10828 1/20 0.63
▸ RECQL P46063 1/20 0.60
▸ LMNA P02545 1/20 0.55
▸ CNR2 P34972 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10714412 0.98 ALDH1A1 (0.68) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL2181401 0.97 ALDH1A1 (0.67) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL3777713 0.84 TDP1 (0.69) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL4060747 0.83 TDP1 (0.67) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL19308757 0.83 ALDH1A1 (0.65) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL2489856 0.83 ALDH1A1 (0.65) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL4084214 0.83 HSD17B10 (1.00) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL133642 0.83 MAPT (1.00) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL3759273 0.82 ALDH1A1 (0.73) ALDH1A1MAPTHSD17B10KDM4EHPGD
Hydrochloric Acid SCHEMBL10859701 0.81 ADORA1 (0.60) ALDH1A1MAPTHSD17B10KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025042610-A1 PIFITHRIN ANALOGUES AND METHODS OF TREATING RETT SYNDROME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-02-27 — — WO claimed
WO-2025093590-A1 HETEROARYL ESTER DERIVATIVES AS SODIUM CHANNEL INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2025-05-08 — — WO disclosed
WO-2025042610-A1 PIFITHRIN ANALOGUES AND METHODS OF TREATING RETT SYNDROME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-02-27 — — WO disclosed
CN-119285624-A Pyrimidine compound containing thiophene, preparation method thereof and application of pyrimidine compound in preparation of medicines with anticancer effect 南方医科大学中西医结合医院 2025-01-10 — — CN disclosed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 — — US disclosed
US-20230278978-A1 THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-09-07 — — US disclosed
US-20230278978-A1 THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-09-07 — — US disclosed
US-20230278978-A1 THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-09-07 — — US disclosed
EP-4185381-A1 THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF Inipharm, Inc. (US) 2023-05-31 — — EP disclosed
US-11603368-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-03-14 — — US disclosed
US-6495554-B2 PHOSPHODIESTERASE V INHIBITORS, TREATING CARDIOVASCULAR DISORDERS, AND THERAPY OF ERECTILE DYSFUNCTION. MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2002-12-17 — — US disclosed
US-20020132818-A1 Thienopyrimidines MERCK PATENT GMBH (DE) 2002-09-19 — — US disclosed
WO-2002062343-A2 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2002-08-15 — — WO disclosed
US-6420368-B1 DISEASES OF THE CARDIOVASCULAR SYSTEM AND FOR TREATMENT AND/OR THERAPY OF ERECTILE DYSFUNCTION. MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2002-07-16 — — US disclosed
US-20020025949-A1 Anti-epileptogenic agents QUEEN'S UNIVERSITY AT KINGSTON 2002-02-28 — — US disclosed
US-6306909-B1 AMINOACID DERIVATIVES AND ESTERS QUEEN'S UNIVERSITY AT KINGSTON (CA) 2001-10-23 — — US disclosed
EP-0969823-A2 ANTI-EPILEPTOGENIC AGENTS QUEEN'S UNIVERSITY AT KINGSTON (CA) 2000-01-12 — — EP disclosed
WO-1998040055-A2 ANTI-EPILEPTOGENIC AGENTS QUEEN'S UNIVERSITY AT KINGSTON (CA) 1998-09-17 — — WO disclosed
EP-0202538-B1 GROWTH PROMOTING AGENTS BAYER AG (DE) 1988-12-28 — — EP disclosed
US-4692461-A PLANT PROTECTION BAYER AKTIENGESELLSCHAFT (DE) 1987-09-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132818-A1 Thienopyrimidines PDE5A, PDE3B, PDE3A ALDH1A1 313/4885MAPT 2897/4885HSD17B10 609/4885
US-20020025949-A1 Anti-epileptogenic agents CA3, GAP43, GRIK5 ALDH1A1 712/4885MAPT 1914/4885HSD17B10 842/4885
US-20230278978-A1 THIOPHENE HSD17B13 INHIBITORS AND USES THEREOF HSD17B3, HSD17B1, HSD17B13 ALDH1A1 237/4885MAPT 2171/4885HSD17B10 6/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 ALDH1A1 233/4885MAPT 2356/4885HSD17B10 1200/4885
US-11603368-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH ALDH1A1 2143/4885MAPT 2107/4885HSD17B10 743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.